EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. / Morbelli, Silvia; Esposito, Giuseppe; Arbizu, Javier; Barthel, Henryk; Boellaard, Ronald; Bohnen, Nico I.; Brooks, David J.; Darcourt, Jacques; Dickson, John C.; Douglas, David; Drzezga, Alexander; Dubroff, Jacob; Ekmekcioglu, Ozgul; Garibotto, Valentina; Herscovitch, Peter; Kuo, Phillip; Lammertsma, Adriaan; Pappata, Sabina; Peñuelas, Iván; Seibyl, John; Semah, Franck; Tossici-Bolt, Livia; Van de Giessen, Elsmarieke; Van Laere, Koen; Varrone, Andrea; Wanner, Michele; Zubal, George; Law, Ian.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 47, No. 8, 2020, p. 1885-1912.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0
AU - Morbelli, Silvia
AU - Esposito, Giuseppe
AU - Arbizu, Javier
AU - Barthel, Henryk
AU - Boellaard, Ronald
AU - Bohnen, Nico I.
AU - Brooks, David J.
AU - Darcourt, Jacques
AU - Dickson, John C.
AU - Douglas, David
AU - Drzezga, Alexander
AU - Dubroff, Jacob
AU - Ekmekcioglu, Ozgul
AU - Garibotto, Valentina
AU - Herscovitch, Peter
AU - Kuo, Phillip
AU - Lammertsma, Adriaan
AU - Pappata, Sabina
AU - Peñuelas, Iván
AU - Seibyl, John
AU - Semah, Franck
AU - Tossici-Bolt, Livia
AU - Van de Giessen, Elsmarieke
AU - Van Laere, Koen
AU - Varrone, Andrea
AU - Wanner, Michele
AU - Zubal, George
AU - Law, Ian
PY - 2020
Y1 - 2020
N2 - Purpose: This joint practice guideline or procedure standard was developed collaboratively by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The goal of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of dopaminergic imaging in parkinsonian syndromes. Methods: Currently nuclear medicine investigations can assess both presynaptic and postsynaptic function of dopaminergic synapses. To date both EANM and SNMMI have published procedural guidelines for dopamine transporter imaging with single photon emission computed tomography (SPECT) (in 2009 and 2011, respectively). An EANM guideline for D2 SPECT imaging is also available (2009). Since the publication of these previous guidelines, new lines of evidence have been made available on semiquantification, harmonization, comparison with normal datasets, and longitudinal analyses of dopamine transporter imaging with SPECT. Similarly, details on acquisition protocols and simplified quantification methods are now available for dopamine transporter imaging with PET, including recently developed fluorinated tracers. Finally, [18F]fluorodopa PET is now used in some centers for the differential diagnosis of parkinsonism, although procedural guidelines aiming to define standard procedures for [18F]fluorodopa imaging in this setting are still lacking. Conclusion: All these emerging issues are addressed in the present procedural guidelines for dopaminergic imaging in parkinsonian syndromes.
AB - Purpose: This joint practice guideline or procedure standard was developed collaboratively by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The goal of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of dopaminergic imaging in parkinsonian syndromes. Methods: Currently nuclear medicine investigations can assess both presynaptic and postsynaptic function of dopaminergic synapses. To date both EANM and SNMMI have published procedural guidelines for dopamine transporter imaging with single photon emission computed tomography (SPECT) (in 2009 and 2011, respectively). An EANM guideline for D2 SPECT imaging is also available (2009). Since the publication of these previous guidelines, new lines of evidence have been made available on semiquantification, harmonization, comparison with normal datasets, and longitudinal analyses of dopamine transporter imaging with SPECT. Similarly, details on acquisition protocols and simplified quantification methods are now available for dopamine transporter imaging with PET, including recently developed fluorinated tracers. Finally, [18F]fluorodopa PET is now used in some centers for the differential diagnosis of parkinsonism, although procedural guidelines aiming to define standard procedures for [18F]fluorodopa imaging in this setting are still lacking. Conclusion: All these emerging issues are addressed in the present procedural guidelines for dopaminergic imaging in parkinsonian syndromes.
KW - Brain
KW - DAT
KW - DOPA
KW - Parkinson
KW - Parkinsonian syndromes
KW - PET
KW - SPECT
UR - http://www.scopus.com/inward/record.url?scp=85084518521&partnerID=8YFLogxK
U2 - 10.1007/s00259-020-04817-8
DO - 10.1007/s00259-020-04817-8
M3 - Journal article
C2 - 32388612
AN - SCOPUS:85084518521
VL - 47
SP - 1885
EP - 1912
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
SN - 1619-7070
IS - 8
ER -
ID: 260307119